Acorda Therapeutics

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acorda Therapeutics Inc.
Type Public
Traded as NASDAQACOR FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founders Ron Cohen
Headquarters Ardsley, New York, United States
Key people Ron Cohen
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$292.2 Million (FY 2011)[2]
Operating income Increase US$35.1 Million (FY 2011)[2]
Net income Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Employees 328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History[edit]

Corporate governance[edit]

As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[4] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.

Products[edit]

Products on the market[edit]

Products under development[edit]

References[edit]

External links[edit]